Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASCO 2020 | Update on CARTITUDE-1: CAR-T in RRMM

Jesús Berdeja • 26 May 2020
ASCO 2020
Multiple Myeloma Ciltacabtagene autoleucel
CARTITUDE-1

Jesus Berdeja, MD, Director of Myeloma Research, Sarah Cannon Research Institute, Nashville, TN, gives an update on CARTITUDE-1 (NCT03548207), a Phase Ib/II study of ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy in relapsed/refractory (R/R) multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Jesús Berdeja

Multiple myeloma highlights at ASH 2020 1:22
Multiple myeloma highlights at ASH 2020
Jesús Berdeja • 11 Dec 2020
CRB-402 study update: T-cell phenotypes in myeloma 2:38
CRB-402 study update: T-cell phenotypes in myeloma
Jesús Berdeja • 11 Dec 2020
Impact of age on ide-cel efficacy in the KarMMa trial 1:55
Impact of age on ide-cel efficacy in the KarMMa trial
Jesús Berdeja • 11 Dec 2020
ASCO 2020: updates in myeloma 1:19
ASCO 2020: updates in myeloma
Jesús Berdeja • 26 May 2020

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals